

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Feige, et al.

Serial No.: Not Yet Received

Group Art Unit No.:

Filed: October 22, 1999

Examiner:

For: Modified Peptides as Therapeutic Agents

Docket No.: A-527

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen, Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,



Timothy J. Gaul  
Attorney for Applicant  
Registration No.: 33,111  
Phone: (805) 447-2688  
Date: October 22, 1999

Please send all future correspondence to:  
U.S. Patent Operations/TJG  
M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

**EXPRESS MAIL CERTIFICATE**

"Express Mail" mail labeling number: EL198799316US

Date of Deposit: October 22, 1999

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Box Patent Application, Assistant Commissioner for Patents, Washington, DC 20231.

Christina Gutierrez  
Printed Name

Christina Gutierrez  
Signature

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Feige, et al.

Serial No.: Not Yet Received

Group Art Unit No.:

Filed: October 22, 1999

Examiner:

## For: Modified Peptides as Therapeutic Agents

Docket No.: A-527



## **INFORMATION DISCLOSURE STATEMENT**

**Assistant Commissioner for Patents  
Washington, D.C. 20231**

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen, Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Timothy J. Gaul  
Attorney for Applicant  
Registration No.: 33,111  
Phone: (805) 447-2688  
Date: October 22, 1999

Please send all future correspondence to:  
U.S. Patent Operations/TJG  
M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

**EXPRESS MAIL CERTIFICATE**

"Express Mail" mail labeling number: EL198799316US

Date of Deposit: October 22, 1999

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Box Patent Application, Assistant Commissioner for Patents, Washington, DC 20231.

Christina Gutierrez  
Printed Name

Christine Mutter  
Signature